Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
about
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancerHigh rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
P2860
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@ast
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@en
type
label
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@ast
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@en
prefLabel
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@ast
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@en
P356
P1476
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
@en
P2093
Clifford Hudis
P356
10.3816/CBC.2006.N.013
P407
P577
2006-04-01T00:00:00Z